Figure 3.
Parameters of RBC-induced clot shrinkage in platelet-depleted reconstituted blood samples in the absence (control) and presence of the following platelet inhibitors. 200 μM Blebb, 4 μM Lat A, and 100 μg/mL Abcixi. (А) The final extent of clot shrinkage. (B) Lag time of clot shrinkage after thrombin-induced clot formation. (C) Area under the kinetic curve. (D) Average shrinking velocity. The results indicate that the platelet antagonists studied have no effect on the RBC-induced clot shrinkage in the absence of platelets. The results from 5 duplicated experiments are presented as the mean ± standard error of the mean. Ordinary 1-way analysis of variance test with Tukey multiple comparisons post hoc test. Abcixi, abciximab; Blebb, blebbistatin; Lat A, latrunculin A; n.s., not significant.

Parameters of RBC-induced clot shrinkage in platelet-depleted reconstituted blood samples in the absence (control) and presence of the following platelet inhibitors. 200 μM Blebb, 4 μM Lat A, and 100 μg/mL Abcixi. (А) The final extent of clot shrinkage. (B) Lag time of clot shrinkage after thrombin-induced clot formation. (C) Area under the kinetic curve. (D) Average shrinking velocity. The results indicate that the platelet antagonists studied have no effect on the RBC-induced clot shrinkage in the absence of platelets. The results from 5 duplicated experiments are presented as the mean ± standard error of the mean. Ordinary 1-way analysis of variance test with Tukey multiple comparisons post hoc test. Abcixi, abciximab; Blebb, blebbistatin; Lat A, latrunculin A; n.s., not significant.

or Create an Account

Close Modal
Close Modal